{"id":45379,"date":"2025-10-31T11:31:07","date_gmt":"2025-10-31T03:31:07","guid":{"rendered":"https:\/\/flcube.com\/?p=45379"},"modified":"2025-10-31T11:31:08","modified_gmt":"2025-10-31T03:31:08","slug":"dizal-pharmaceutical-reports-73-revenue-growth-driven-by-sunvozertinib-and-golidocitinib","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=45379","title":{"rendered":"Dizal Pharmaceutical Reports 73% Revenue Growth, Driven by Sunvozertinib and Golidocitinib"},"content":{"rendered":"\n<p><strong>Dizal Pharmaceutical Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/688192:SHA\">SHA: 688192<\/a>) announced its <strong>2025 third\u2011quarter earnings<\/strong> today, reporting operating revenue of <strong>\u00a5586\u202fmillion<\/strong>, a <strong>73\u202f% year\u2011on\u2011year increase<\/strong>. The jump is largely attributable to the expanded market penetration of its core products <strong>Sunvozertinib<\/strong> and <strong>Golidocitinib<\/strong> following their inclusion on the National Reimbursement Drug List (NRDL).<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-highlights\"><strong>Financial Highlights<\/strong><\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>Q3\u202f2025<\/th><th>YoY Change<\/th><\/tr><\/thead><tbody><tr><td>Operating Revenue<\/td><td>\u00a5586\u202fmillion<\/td><td>+73\u202f%<\/td><\/tr><tr><td>Core\u2011Product Sales (Sunvozertinib + Golidocitinib)<\/td><td>70\u202f% of total<\/td><td>+85\u202f%<\/td><\/tr><tr><td>R&amp;D Expenditure<\/td><td>\u00a542\u202fmillion<\/td><td>+15\u202f%<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>NRDL Impact<\/strong> \u2013 The NRDL listing has accelerated volume growth, driving both market share and top\u2011line revenue.<\/li>\n\n\n\n<li><strong>Stable Cash Flow<\/strong> \u2013 Despite increased R&amp;D outlays, operating cash flow remains positive, supporting future pipeline investments.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-pipeline-amp-r-amp-d-progress\"><strong>Pipeline &amp; R&amp;D Progress<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Birelentinib (DZD8586)<\/strong> \u2013 A global first\u2011in\u2011class LYN\/BTK dual\u2011target inhibitor, has entered <strong>Phase\u202fIII<\/strong> trials worldwide and received <strong>Fast\u2011Track Designation<\/strong> from the U.S. FDA.<\/li>\n\n\n\n<li><strong>DZD6008<\/strong> \u2013 A fourth\u2011generation EGFR TKI, is progressing its dose\u2011expansion study in EGFR\u2011mutated non\u2011small\u2011cell lung cancer (NSCLC).<\/li>\n\n\n\n<li><strong>Seven Global Pipelines<\/strong> \u2013 Dizal maintains full global rights to seven small\u2011molecule candidates, each with First\u2011in\u2011Class (FIC) or Best\u2011in\u2011Class (BIC) potential.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-outlook\"><strong>Strategic Outlook<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>NRDL Momentum<\/strong> \u2013 Continued inclusion of Sunvozertinib and Golidocitinib is expected to sustain revenue growth through 2026.<\/li>\n\n\n\n<li><strong>R&amp;D Pipeline<\/strong> \u2013 Successful Phase\u202fIII data for Birelentinib and dose\u2011expansion milestones for DZD6008 will expand the company\u2019s therapeutic footprint.<\/li>\n\n\n\n<li><strong>Global Expansion<\/strong> \u2013 Full ownership of pipeline assets positions Dizal for strategic license or partnership deals in key international markets.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This release contains forward\u2011looking statements that involve risks and uncertainties. Actual results may differ materially.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Dizal Pharmaceutical Co., Ltd. (SHA: 688192) announced its 2025 third\u2011quarter earnings today, reporting operating revenue&#8230;<\/p>\n","protected":false},"author":1,"featured_media":45380,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[191,27,981],"class_list":["post-45379","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-dizal-pharmaceutical","tag-finanical-reports","tag-sha-688192"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Dizal Pharmaceutical Reports 73% Revenue Growth, Driven by Sunvozertinib and Golidocitinib - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Dizal Pharmaceutical Co., Ltd. (SHA: 688192) announced its 2025 third\u2011quarter earnings today, reporting operating revenue of \u00a5586\u202fmillion, a 73\u202f% year\u2011on\u2011year increase. The jump is largely attributable to the expanded market penetration of its core products Sunvozertinib and Golidocitinib following their inclusion on the National Reimbursement Drug List (NRDL).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=45379\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Dizal Pharmaceutical Reports 73% Revenue Growth, Driven by Sunvozertinib and Golidocitinib\" \/>\n<meta property=\"og:description\" content=\"Dizal Pharmaceutical Co., Ltd. (SHA: 688192) announced its 2025 third\u2011quarter earnings today, reporting operating revenue of \u00a5586\u202fmillion, a 73\u202f% year\u2011on\u2011year increase. The jump is largely attributable to the expanded market penetration of its core products Sunvozertinib and Golidocitinib following their inclusion on the National Reimbursement Drug List (NRDL).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=45379\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-31T03:31:07+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-31T03:31:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/3103.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45379#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45379\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Dizal Pharmaceutical Reports 73% Revenue Growth, Driven by Sunvozertinib and Golidocitinib\",\"datePublished\":\"2025-10-31T03:31:07+00:00\",\"dateModified\":\"2025-10-31T03:31:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45379\"},\"wordCount\":276,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45379#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/3103.webp\",\"keywords\":[\"Dizal Pharmaceutical\",\"Finanical Reports\",\"SHA: 688192\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=45379#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45379\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=45379\",\"name\":\"Dizal Pharmaceutical Reports 73% Revenue Growth, Driven by Sunvozertinib and Golidocitinib - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45379#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45379#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/3103.webp\",\"datePublished\":\"2025-10-31T03:31:07+00:00\",\"dateModified\":\"2025-10-31T03:31:08+00:00\",\"description\":\"Dizal Pharmaceutical Co., Ltd. (SHA: 688192) announced its 2025 third\u2011quarter earnings today, reporting operating revenue of \u00a5586\u202fmillion, a 73\u202f% year\u2011on\u2011year increase. The jump is largely attributable to the expanded market penetration of its core products Sunvozertinib and Golidocitinib following their inclusion on the National Reimbursement Drug List (NRDL).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45379#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=45379\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45379#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/3103.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/3103.webp\",\"width\":1080,\"height\":608,\"caption\":\"Dizal Pharmaceutical Reports 73% Revenue Growth, Driven by Sunvozertinib and Golidocitinib\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45379#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Dizal Pharmaceutical Reports 73% Revenue Growth, Driven by Sunvozertinib and Golidocitinib\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Dizal Pharmaceutical Reports 73% Revenue Growth, Driven by Sunvozertinib and Golidocitinib - Insight, China&#039;s Pharmaceutical Industry","description":"Dizal Pharmaceutical Co., Ltd. (SHA: 688192) announced its 2025 third\u2011quarter earnings today, reporting operating revenue of \u00a5586\u202fmillion, a 73\u202f% year\u2011on\u2011year increase. The jump is largely attributable to the expanded market penetration of its core products Sunvozertinib and Golidocitinib following their inclusion on the National Reimbursement Drug List (NRDL).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=45379","og_locale":"en_US","og_type":"article","og_title":"Dizal Pharmaceutical Reports 73% Revenue Growth, Driven by Sunvozertinib and Golidocitinib","og_description":"Dizal Pharmaceutical Co., Ltd. (SHA: 688192) announced its 2025 third\u2011quarter earnings today, reporting operating revenue of \u00a5586\u202fmillion, a 73\u202f% year\u2011on\u2011year increase. The jump is largely attributable to the expanded market penetration of its core products Sunvozertinib and Golidocitinib following their inclusion on the National Reimbursement Drug List (NRDL).","og_url":"https:\/\/flcube.com\/?p=45379","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-10-31T03:31:07+00:00","article_modified_time":"2025-10-31T03:31:08+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/3103.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=45379#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=45379"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Dizal Pharmaceutical Reports 73% Revenue Growth, Driven by Sunvozertinib and Golidocitinib","datePublished":"2025-10-31T03:31:07+00:00","dateModified":"2025-10-31T03:31:08+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=45379"},"wordCount":276,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=45379#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/3103.webp","keywords":["Dizal Pharmaceutical","Finanical Reports","SHA: 688192"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=45379#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=45379","url":"https:\/\/flcube.com\/?p=45379","name":"Dizal Pharmaceutical Reports 73% Revenue Growth, Driven by Sunvozertinib and Golidocitinib - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=45379#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=45379#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/3103.webp","datePublished":"2025-10-31T03:31:07+00:00","dateModified":"2025-10-31T03:31:08+00:00","description":"Dizal Pharmaceutical Co., Ltd. (SHA: 688192) announced its 2025 third\u2011quarter earnings today, reporting operating revenue of \u00a5586\u202fmillion, a 73\u202f% year\u2011on\u2011year increase. The jump is largely attributable to the expanded market penetration of its core products Sunvozertinib and Golidocitinib following their inclusion on the National Reimbursement Drug List (NRDL).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=45379#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=45379"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=45379#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/3103.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/3103.webp","width":1080,"height":608,"caption":"Dizal Pharmaceutical Reports 73% Revenue Growth, Driven by Sunvozertinib and Golidocitinib"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=45379#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Dizal Pharmaceutical Reports 73% Revenue Growth, Driven by Sunvozertinib and Golidocitinib"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/3103.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45379","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=45379"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45379\/revisions"}],"predecessor-version":[{"id":45381,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45379\/revisions\/45381"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/45380"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=45379"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=45379"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=45379"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}